Zdrowie i gospodarka · 13/04/2011
FDA Clears NOVANTRONE Injection for Sale, Citing Lack of Safety or Effectiveness Concerns
The US Food and Drug Administration (FDA) has announced that NOVANTRONE (mitoxantrone hydrochloride) Injection, available in two different strengths, will not be withdrawn from sale due to concerns over its safety or effectiveness, allowing the FDA to continue approving abbreviated new drug applications (ANDAs) for the product.